Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more
Sun Pharma Advanced Research Company Limited (SPARC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.336x
Based on the latest financial reports, Sun Pharma Advanced Research Company Limited (SPARC) has a cash flow conversion efficiency ratio of 0.336x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹-1.16 Billion) by net assets (₹-3.45 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sun Pharma Advanced Research Company Limited - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Sun Pharma Advanced Research Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sun Pharma Advanced Research Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sun Pharma Advanced Research Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wallix Group SA
PA:ALLIX
|
0.192x |
|
Altinkilic Gida ve Sut Sanayi Ticaret A.S.
IS:ALKLC
|
-0.197x |
|
Copper 360 Ltd
JSE:CPR
|
N/A |
|
91App Inc
TWO:6741
|
0.010x |
|
Wuhu Fuchun Dye and Weave Co.Ltd.
SHG:605189
|
0.362x |
|
MNtech Co. Ltd
KQ:095500
|
0.089x |
|
DOWAY
PINK:DOWAY
|
-0.872x |
|
Salmon Evolution Holding AS
OL:SALME
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Sun Pharma Advanced Research Company Limited (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sun Pharma Advanced Research Company Limited from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹-2.17 Billion | ₹-3.60 Billion | 1.661x | +148.66% |
| 2024-03-31 | ₹1.26 Billion | ₹-4.29 Billion | -3.413x | -2431.86% |
| 2023-03-31 | ₹5.13 Billion | ₹-691.20 Million | -0.135x | +97.98% |
| 2022-03-31 | ₹312.26 Million | ₹-2.08 Billion | -6.669x | -838.67% |
| 2021-03-31 | ₹-1.68 Billion | ₹-1.52 Billion | 0.903x | -92.02% |
| 2020-03-31 | ₹-186.38 Million | ₹-2.11 Billion | 11.310x | +2048.94% |
| 2019-03-31 | ₹2.96 Billion | ₹-1.72 Billion | -0.580x | +41.35% |
| 2018-03-31 | ₹1.85 Billion | ₹-1.83 Billion | -0.989x | -23.37% |
| 2017-03-31 | ₹1.60 Billion | ₹-1.28 Billion | -0.802x | +45.76% |
| 2016-03-31 | ₹299.03 Million | ₹-442.12 Million | -1.479x | -272.84% |
| 2015-03-31 | ₹997.99 Million | ₹-395.76 Million | -0.397x | -249.72% |
| 2014-03-31 | ₹1.39 Billion | ₹368.95 Million | 0.265x | +130.12% |
| 2013-03-31 | ₹1.08 Billion | ₹-953.44 Million | -0.879x | -184.34% |
| 2012-03-31 | ₹-666.09 Million | ₹-694.49 Million | 1.043x | +134.07% |
| 2011-03-31 | ₹56.23 Million | ₹25.05 Million | 0.445x | -50.20% |
| 2010-03-31 | ₹141.24 Million | ₹126.34 Million | 0.895x | +25.38% |
| 2009-03-31 | ₹356.78 Million | ₹254.54 Million | 0.713x | +256.80% |
| 2008-03-31 | ₹448.18 Million | ₹-203.92 Million | -0.455x | -54787.50% |
| 2007-03-31 | ₹497.01 Million | ₹-412.00K | -0.001x | -- |